Revance Therapeutics, Inc. (NASDAQ:RVNC)

About the company

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

193

CEO

Mark J. Foley

Exchange

NASDAQ

Website

http://www.revance.com

$0.00M

Total Revenue

193

Employees

$1B

Market Capitalization

-6.38

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 12180.00 1376.00 5.19 19.21 43.06
Catalent, Inc. CTLT 10896.37 2872.00 5.47 104.47 3.63
Perrigo Co. Plc PRGO 7433.62 4837.00 1.27 50.71 3.02
Bausch Health Cos., Inc. BHC 6195.15 8597.00 8.65 -3.27 -21.96
Jazz Pharmaceuticals Plc JAZZ 6047.70 2188.00 2.09 22.10 12.81
United Therapeutics Corp. UTHR 5027.56 1443.00 1.75 9.70 36.59
MyoKardia, Inc. MYOK 4249.02 34.00 12.35 -13.70 -201.73
Axsome Therapeutics, Inc. AXSM 3004.40 None 20.39 -33.40 None
Pacira Biosciences, Inc. PCRX 2415.84 435.00 6.48 -5752.00 -0.02
SAGE Therapeutics, Inc. SAGE 2295.80 9.00 2.70 -3.55 -413.06
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
Corcept Therapeutics, Inc. CORT 2043.50 335.00 4.69 19.25 31.64
Prestige Consumer Healthcare, Inc. PBH 1816.11 963.00 1.53 12.81 14.77
Revolution Medicines, Inc. RVMD 1631.94 48.00 4.24 -23.05 -146.29
Madrigal Pharmaceuticals, Inc. MDGL 1615.50 0.00 4.31 -15.81 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1548.02 440.00 -21.91 18.26 19.14
Innoviva, Inc. INVA 1534.54 285.00 3.63 7.94 66.41
Intercept Pharmaceuticals, Inc. ICPT 1446.72 272.00 -43.06 -4.22 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Supernus Pharmaceuticals, Inc. SUPN 1274.94 402.00 2.02 10.93 28.90
Zogenix, Inc. ZGNX 1251.45 5.00 3.42 -2.94 -241.62
Theravance Biopharma, Inc. TBPH 1220.94 88.00 -8.57 -4.95 -280.80
Revance Therapeutics, Inc. RVNC 1190.98 0.00 4.70 -6.38 41.82
Amphastar Pharmaceuticals, Inc. AMPH 1020.18 327.00 2.55 20.02 15.90
Endo International Plc ENDP 766.08 3014.00 -1.05 -2.73 -9.09
BellRing Brands, Inc. BRBR 745.68 954.00 -0.40 5.66 13.98
Assembly Biosciences, Inc. ASMB 680.34 16.00 3.05 -6.84 -601.75
Eagle Pharmaceuticals, Inc. EGRX 648.90 192.00 3.49 257.50 1.29
Aerie Pharmaceuticals, Inc. AERI 616.86 79.00 4.89 -3.05 -252.92
Collegium Pharmaceutical, Inc. COLL 582.76 299.00 4.17 -45.11 -4.21
Catalyst Pharmaceuticals, Inc. CPRX 536.07 119.00 5.22 12.22 36.09
Anika Therapeutics, Inc. ANIK 486.78 125.00 1.68 17.56 22.73
Intersect ENT, Inc. XENT 445.76 102.00 4.21 -8.93 -48.61
BioDelivery Sciences International, Inc. BDSI 389.25 130.00 5.57 -52.89 -5.01
ANI Pharmaceuticals, Inc. ANIP 367.56 203.00 1.88 -235.62 -0.67
Albireo Pharma, Inc. ALBO 329.29 11.00 3.35 -4.31 -730.55
MEI Pharma, Inc. MEIP 285.52 5.00 4.91 -7.32 -539.48
Mallinckrodt Plc MNK 199.08 3037.00 0.11 -0.17 -39.56
Marinus Pharmaceuticals, Inc. MRNS 151.20 0.00 5.85 -2.24 None
Agile Therapeutics, Inc. AGRX 147.85 None 2.41 -7.16 None
Cerecor, Inc. CERC 117.76 7.00 7.53 -5.22 -429.22
Ampio Pharmaceuticals, Inc. AMPE 98.38 1.00 68.80 -5.29 None
Evoke Pharma, Inc. EVOK 85.92 None 29.83 -12.79 None
CTI BioPharma Corp. CTIC 83.78 3.00 3.74 -2.03 -111.83
AcelRx Pharmaceuticals, Inc. ACRX 83.47 2.00 -1.53 -1.49 -644.25
Zynerba Pharmaceuticals, Inc. ZYNE 79.12 0.00 1.30 -2.21 -699.94
Aclaris Therapeutics, Inc. ACRS 73.80 4.00 1.29 -0.54 None
Adamas Pharmaceuticals, Inc. ADMS 70.84 57.00 -4.52 -0.76 -160.44
Oramed Pharmaceuticals, Inc. ORMP 61.02 3.00 4.91 -4.77 -464.15
Cassava Sciences, Inc. SAVA 58.14 41.00 3.06 -12.75 76.71
SCYNEXIS, Inc. SCYX 48.69 0.00 10.23 -1.26 -30.84
Cumberland Pharmaceuticals, Inc. CPIX 48.00 47.00 0.98 -10.67 -9.59
Natural Alternatives International, Inc. NAII 47.67 114.00 0.65 -12.61 -3.19
IsoRay, Inc. ISR 46.90 9.00 8.75 -14.00 -36.08
Lipocine, Inc. LPCN 39.90 0.00 9.50 -2.66 None
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.50 65.00 -2.65 -1.97 -26.74
PLx Pharma, Inc. PLXP 25.88 0.00 -2.48 -2.74 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 20.80 3.00 2.59 -1.76 -264.21
Regulus Therapeutics, Inc. RGLS 17.49 0.00 1.54 -0.82 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.40 8.00 0.66 -0.15 -798.18
Intec Pharma Ltd. NTEC 10.18 None 1.31 -0.24 None
Hepion Pharmaceuticals, Inc. HEPA 7.38 None 2.31 -0.62 None
Sonoma Pharmaceuticals, Inc. SNOA 6.35 19.00 1.01 -2.04 -25.58
VIVUS, Inc. VVUS 6.27 73.00 -0.14 -0.21 -39.28
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
Tonix Pharmaceuticals Holding Corp. TNXP 4.62 None 1.16 -0.10 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Is Revance Therapeutics Inc (RVNC) Going to Burn These Hedge Funds?

4d ago, source: YAHOO!

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will ...

NetworkNewsBreaks - Revance Therapeutics Inc. (NASDAQ: RVNC) Featured in Mizuho Securities Research Report

9d ago, source: MarketWatch

Revance Therapeutics Inc. (NASDAQ: RVNC) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, "Revance announced positive results from two phase 2a ...

Revance Therapeutics Inc (NASDAQ:RVNC) Given Average Recommendation of “Buy” by Analysts

10d ago, source: theenterpriseleader.com

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have earned a consensus recommendation of “Buy” from the eleven research ...

Nuveen Asset Management LLC Increases Position in Revance Therapeutics Inc (NASDAQ:RVNC)

11d ago, source: theenterpriseleader.com

Nuveen Asset Management LLC grew its stake in Revance Therapeutics Inc (NASDAQ:RVNC) by 7.5% during the first quarter, ...

Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection

9d ago, source: MarketWatch

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its ...

BRIEF-Revance Announces Positive Results In Two Phase 2A Studies For Treatment Of Forehead Lines And Crow’s Feet

9d ago, source: Reuters

REVANCE ANNOUNCES POSITIVE RESULTS IN TWO PHASE 2A STUDIES OF DAXIBOTULINUMTOXINA FOR INJECTION FOR TREATMENT OF FOREHEAD LINES AND CROW’S FEET, RESPECTIVELY * REVANCE THERAPEUTICS INC - AT LEAST ONE ...

Global Botulinum Market is Expected to Reach at a CAGR of 8.16% from 2018 to 2025

4d ago, source: PharmiWeb

Inc. (US), Lanzhou Institute of Biological Products Co. Ltd., Revance Therapeutics, Inc., Huons Global, Evolus, Inc, Hugel among others. To satisfy the ever rising demand for the botulinum for the ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.